Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Peladawnon Apr 30, 2024 6:06pm
106 Views
Post# 36016028

RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….

RE:RE:RE:RE:“Conference call to discuss “A” corporate update”….Cf....we get what you're saying, but, is nobody else even the least bit curious, besides Angler and myself, the way they worded this news release...It started out....."Conference call to discuss 1st quarter  fin. results and op. highlights".....and then goes on to say "to discuss 'a' corporate update and financial results. ....maybe I'm reading way too much into it, but it does seem a little overly specific to say 'a' corporate update (singular)...I mean, they could just as easily have said "corporate updates and financial results, no?....call me crazy but I sense something other than just your average quarterly report.
<< Previous
Bullboard Posts
Next >>